Quality of life and functional capacity outcomes in the MOMENTUM 3 trial at 6 months: A call for new metrics for left ventricular assist device patients

Determinants of Functional Capacity and Quality of Life After Implantation of a Durable Left Ventricular Assist Device

“…[ 9 , 49 ] Studies are remarkably consistent in finding that approximately 80% of patients are in NYHA Class I–II after implantation, and the improvement in symptoms has been documented to be sustained over time. [ 9 , 20 , 49 ] However, some patients (<5%) remain severely symptomatic (NYHA Class IV) even 12 months after LVAD implantation. [ 9 , 49 ]…”

“…[ 9 , 20 , 49 ] However, some patients (<5%) remain severely symptomatic (NYHA Class IV) even 12 months after LVAD implantation. [ 9 , 49 ]…”

Implantation of a fully magnetically levitated left ventricular assist device using a sternal-sparing surgical technique

“…6 In a secondary analysis of the Momentum 3 data, 77% of HM3 patients were in NYHA Class I or II at 6 months. 22 After hospital discharge, the SS cohort spent 98% of the time outside the hospital, with a readmission rate of 27% at 6 months. Reasons for readmission included heart failure, gastrointestinal bleeding, and infection of the left thoracotomy incision.…”

Left ventricular assist systems and infection-related outcomes: A comprehensive analysis of the MOMENTUM 3 trial

“…3 However, non−hemocompatibility-related outcomes continue to persist and determine quality of life and overall outcomes with LVADs, which are principally driven by infections and the morbidity conferred by the presence of an external driveline to power the device. 4,5 The MOMENTUM 3 trial, which randomized patients with advanced heart failure refractory to medical therapy to either the HM3 LVAD or the HeartMate II (HMII) axialflow LVAD and followed them for 2 years, provides a contemporary experience to evaluate the outcomes of infectionrelated events. 1,2 In this comprehensive analysis of the trial, we sought to assess the incidence, clinical patterns, risk markers, and impact of infection-related adverse events.…”